Ann: Race Strategic Update August 2023, page-170

Begs the question why we didn't come out from under the radar after the FTO/Cardio findings and a few pre-clinicals, a few were calling for giving up some IP back then and getting on with it. And before its said that we didn't have the data to take forward

That goes against the many Pre-clinical deals happening in the Mrna space with upfront cash, milestone, and future royalties in play.

We would of at least been Marketing Internationally at $3-4 with high expectations and tight hands from retail shareholders.

Now we are well and truly coming out from under the radar with more data, more disgruntled shareholders, and at $1.

For all my positivity, i feel RAC cocked this part up.